Supporter
    51.
    发明申请
    Supporter 审中-公开
    支持者

    公开(公告)号:US20140288474A1

    公开(公告)日:2014-09-25

    申请号:US14298346

    申请日:2014-06-06

    CPC classification number: A61F5/028 A61F5/024 A61F5/03

    Abstract: A supporter includes a body section having a back-contact section, a first auxiliary band section of which one end is fixed to the top end of a left side of the back-contact section and the other end is fixed to the bottom end of a right side of the back-contact section, a second auxiliary band section forming a pair with the first auxiliary band section, a first ring arranged to slide between the one end and the other end of the first auxiliary band section, a second ring forming a pair with the first ring, a first adjustment band section of which one end is fixed to loops on a right end side of the body section and the other end can be fastened to loops on the right end side of the body section, and a second adjustment band section forming a pair with the first adjustment band section.

    Abstract translation: 支撑体包括具有背接触部分的主体部分,第一辅助带部分,其一端固定到后接触部分的左侧的顶端,另一端固定到底接触部分的底端 所述后接触部分的右侧,与所述第一辅助带部分形成一对的第二辅助带部分,布置成在所述第一辅助带部分的一端和另一端之间滑动的第一环,形成 与第一环对置,第一调节带部分,其一端被固定在环绕在主体部分的右端侧上,另一端可以紧固到主体部分的右端侧上的环,并且第二调节带部分 调整带段与第一调整带段形成一对。

    PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR NON-ALCOHOLIC STEATOHEPATITIS
    52.
    发明申请
    PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR NON-ALCOHOLIC STEATOHEPATITIS 审中-公开
    非酒精性止痛药的预防和/或治疗药物

    公开(公告)号:US20140221390A1

    公开(公告)日:2014-08-07

    申请号:US14162181

    申请日:2014-01-23

    CPC classification number: C07D401/12 A61K31/496

    Abstract: Provided is a compound useful in the prevention and treatment of non-alcoholic steatohepatitis. A prophylactic and/or therapeutic agent for non-alcoholic steatohepatitis which contains, as the active ingredient, 2-[4-[2-(benzimidazol-2-ylthio)ethyl]piperazin-1-yl]-N-[2,4-bis(methylthio)-6-methyl-3-pyridyl]acetamide, an acid-addition salt thereof, or a solvate of the same.

    Abstract translation: 提供了用于预防和治疗非酒精性脂肪性肝炎的化合物。 含有作为活性成分的2- [4- [2-(苯并咪唑-2-基硫基)乙基]哌嗪-1-基] -N- [2,4(ⅰ))的非酒精性脂肪性肝炎的预防和/或治疗剂 - 双(甲硫基)-6-甲基-3-吡啶基]乙酰胺,其酸加成盐或其溶剂合物。

    CELL FUSION PROMOTER AND UTILIZATION OF THE SAME
    53.
    发明申请
    CELL FUSION PROMOTER AND UTILIZATION OF THE SAME 审中-公开
    细胞融合促进剂及其利用

    公开(公告)号:US20140044683A1

    公开(公告)日:2014-02-13

    申请号:US14022983

    申请日:2013-09-10

    Abstract: The present invention provides a regeneration promoter for regenerating tissue with the use of somatic stem cells. The invention also provides a cell fusion promoter comprising ATP or its metabolite which is safely usable in vivo, a method of producing fused cells in the presence of ATP or its metabolite and a related pharmaceutical composition for regenerating or improving the function of a tissue or an organ in a subject suffering from dysfunction or hypofunction due to injury or denaturation.

    Abstract translation: 本发明提供了使用体细胞干细胞再生组织的再生促进剂。 本发明还提供了包含可在体内安全使用的ATP或其代谢物的细胞融合启动子,在ATP或其代谢物存在下产生融合细胞的方法和用于再生或改善组织或功能的功能的相关药物组合物 患有由于损伤或变性引起的功能障碍或功能衰竭的受试者的器官。

    NOVEL PHENYLPYRIDINE DERIVATIVE AND DRUG CONTAINING SAME
    54.
    发明申请
    NOVEL PHENYLPYRIDINE DERIVATIVE AND DRUG CONTAINING SAME 有权
    新颖的吡啶衍生物和含有其的药物

    公开(公告)号:US20140011823A1

    公开(公告)日:2014-01-09

    申请号:US14005046

    申请日:2012-03-13

    CPC classification number: C07D413/14 A61K31/506 C07D401/14

    Abstract: The present invention provides: a compound represented by general formula (I) below, that has both angiotensin II receptor antagonism and a PPARγ activation effect and that is useful as a preventative and/or therapeutic agent for high blood pressure, cardiac disease, arteriosclerosis, type-2 diabetes, and the like; and a drug composition containing the compound. General formula (I) (in the formula: ring A represents a pyridine ring; ring B represents a tetrazole ring or an oxadiazol-5(4H)-one ring; X represents C—R5 or a nitrogen atom; R1 represents an alkyl group; R2 represents an alkyl group or a cycloalkyl group; and R3, R4, and R5 each independently represents a hydrogen atom, a halogen atom, an alkyl group, an alkoxy group or similar.

    Abstract translation: 本发明提供:下述通式(I)表示的化合物,既具有血管紧张素II受体拮抗作用又具有PPARγ活化作用,可用作高血压,心脏病,动脉硬化等的预防和/或治疗剂, 2型糖尿病等; 和含有该化合物的药物组合物。 通式(I)(式中,环A表示吡啶环;环B表示四唑环或恶二唑-5(4H) - 酮环; X表示C-R5或氮原子; R1表示烷基 ; R 2表示烷基或环烷基; R 3,R 4和R 5各自独立地表示氢原子,卤素原子,烷基,烷氧基等。

    Method for measuring physiologically active substance of biological origin, program for implementing the same, and apparatus for measuring physiologically active substance of biological origin
    55.
    发明授权
    Method for measuring physiologically active substance of biological origin, program for implementing the same, and apparatus for measuring physiologically active substance of biological origin 失效
    用于测量生物来源的生理活性物质的方法,其实施方案以及用于测量生物来源的生理活性物质的装置

    公开(公告)号:US08507282B2

    公开(公告)日:2013-08-13

    申请号:US13256427

    申请日:2010-03-12

    CPC classification number: G01N33/579 G01N21/82 Y10T436/143333

    Abstract: When assessing the start time of the limulus reaction between biogenous biologically active substances and LAL and using the reaction start time to determine the concentration of the biogenous biologically active substances, in order to exclude the influence of progressive changes which occur regardless of the conditions of the limulus reaction, the strength of transmitted light or scattered light in the liquid mixture of the measurement sample and LAL is detected, the variation (delta) in the transmittance or number of gel particles is acquired at set intervals, and the time when the variation (delta) crosses a threshold value is taken as the reaction start time. Furthermore, the time intervals when acquiring the abovementioned delta are not uniform, and either change over time from the start of measurement as defined by a time function, or multiple sequences with differing time intervals are prepared in advance.

    Abstract translation: 当评估生物生物活性物质与LAL之间的鲎反应的开始时间并且使用反应开始时间来确定生物生物活性物质的浓度时,为了排除发生的进行性变化的影响,而不管 鲎反应检测到测量样品和LAL的液体混合物中的透射光或散射光的强度,凝胶颗粒的透射率或数量的变化(delta)以设定的间隔获得,并且变化( delta)跨越阈值作为反应开始时间。 此外,获取上述增量的时间间隔是不均匀的,并且随着时间函数定义的测量开始的时间而改变,或者预先准备具有不同时间间隔的多个序列。

    FIXATION LAMP FOR OPHTHALMOLOGICAL INSTRUMENTS
    56.
    发明申请
    FIXATION LAMP FOR OPHTHALMOLOGICAL INSTRUMENTS 有权
    用于眼科仪器的固定灯

    公开(公告)号:US20130148082A1

    公开(公告)日:2013-06-13

    申请号:US13817603

    申请日:2011-08-08

    Applicant: Takuya Hara

    Inventor: Takuya Hara

    CPC classification number: A61B3/0091 A61B3/0075 A61B3/14 F21V21/28

    Abstract: [Problem] To increase, compared to conventional devices, the range of motion of the light emitter (fixation lamp) in an external fixation lamp for an ophthalmological instrument and allow movement of the light emitter to arbitrary positions.[Solution] The fixation lamp (1) has a first arm (A1), which supports a light emitter (2) and is supported by a second arm (A2) via a first joint (C1), and is configured so that the first arm (A1) is able to revolve around at least two axes of revolution (E1, E2) by means of the first joint (C1) and said axes of rotation (E1, E2) are not disposed on the same line. Thereby, the range in which the light emitter (2) can be moved can be increased compared to conventional devices and the light emitter can be moved to an arbitrary position in an arbitrary direction.

    Abstract translation: [问题]与传统装置相比,增加用于眼科仪器的外部固定灯中的光发射器(固定灯)的运动范围并允许光发射器移动到任意位置。 [解决方案]固定灯(1)具有第一臂(A1),其支撑发光体(2),并且经由第一接头(C1)由第二臂(A2)支撑,并且被构造成使得第一 臂(A1)能够通过第一接头(C1)绕至少两个旋转轴线(E1,E2)旋转,并且所述旋转轴线(E1,E2)不设置在同一直线上。 由此,与以往的装置相比,可以使发光体(2)能够移动的范围增大,能够使发光体向任意方向移动到任意位置。

    TELEPHOTO LENS UNIT
    57.
    发明申请
    TELEPHOTO LENS UNIT 审中-公开
    电视镜头单元

    公开(公告)号:US20130094101A1

    公开(公告)日:2013-04-18

    申请号:US13805889

    申请日:2011-06-23

    Inventor: Yasunari Oguchi

    CPC classification number: G02B13/02 G02B7/14 G03B17/14 G03B17/48 G03B17/565

    Abstract: A telephoto lens unit (1) having a lens barrel that supports a telephoto lens and capable of being mounted on and dismounted from a camera body (16) comprises a front lens barrel section (11) that supports the telephoto lens with the subject side defined as the front, and a rear lens barrel section (13) that can be mounted on and dismounted from the front lens barrel section. The distance from the image-most surface of the telephoto lens to the image formation plane of the telephoto lens is kept sufficiently long. Converter lens units (12, 14) for elongating or shortening the focal distance are mounted on the front lens barrel section (11) instead of the rear lens barrel section (13) to provide interchangeable telephoto lenses for a camera having different focal lengths. Also, an erecting prism unit (15) and an eyepiece unit (17) can be connected instead of the rear lens barrel section to enable the telephoto lens to function as a terrestrial telescope.

    Abstract translation: 具有支撑长焦镜头并且能够安装在照相机主体(16)上和从照相机主体(16)上卸下的镜筒的长焦镜头单元(1)包括:前透镜镜筒部分(11),其支撑被摄体侧限定的远摄镜头 以及可以从前镜筒部分安装和拆卸的后镜筒部分(13)。 从长焦镜头的最上表面到长焦镜头的图像形成面的距离保持足够长。 用于延长或缩短焦距的转换器透镜单元(12,14)代替后透镜镜筒部分(13)安装在前镜筒部分(11)上,以提供具有不同焦距的照相机的可互换的长焦镜头。 此外,可以连接竖立棱镜单元(15)和目镜单元(17)而不是后透镜筒部分,以使长焦镜头能够用作地面望远镜。

    Retrovirus-infection inhibitor
    58.
    发明授权
    Retrovirus-infection inhibitor 有权
    逆转录病毒感染抑制剂

    公开(公告)号:US08415399B2

    公开(公告)日:2013-04-09

    申请号:US13246066

    申请日:2011-09-27

    CPC classification number: A61K31/202

    Abstract: An infection inhibitor of retrovirus, particularly human immunodeficiency virus, comprising, as an active ingredient, at least one compound selected from the group consisting of a compound represented by the formula (I) (GGA) or a salt thereof, a compound represented by the formula (II) (NIK-333) or a salt thereof, and derivatives thereof.

    Abstract translation: 一种逆转录病毒感染抑制剂,特别是人类免疫缺陷病毒,包含作为活性成分的至少一种选自由式(I)表示的化合物(GGA)或其盐的化合物,由 式(II)(NIK-333)或其盐及其衍生物。

    PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR NON-ALCOHOLIC STEATOHEPATITIS
    59.
    发明申请
    PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR NON-ALCOHOLIC STEATOHEPATITIS 审中-公开
    非酒精性止痛药的预防和/或治疗药物

    公开(公告)号:US20130066075A1

    公开(公告)日:2013-03-14

    申请号:US13697836

    申请日:2011-05-18

    CPC classification number: C07D401/12 A61K31/496

    Abstract: Provided is a compound useful in the prevention and treatment of non-alcoholic steatohepatitis. A prophylactic and/or therapeutic agent for non-alcoholic steatohepatitis which contains, as the active ingredient, 2-[4-[2-(benzimidazol-2-ylthio)ethyl]piperazin-1-yl]-N-[2,4-bis(methylthio)-6-methyl-3-pyridyl]acetamide, an acid-addition salt thereof, or a solvate of the same.

    Abstract translation: 提供了用于预防和治疗非酒精性脂肪性肝炎的化合物。 含有作为活性成分的2- [4- [2-(苯并咪唑-2-基硫基)乙基]哌嗪-1-基] -N- [2,4(ⅰ))的非酒精性脂肪性肝炎的预防和/或治疗剂 - 双(甲硫基)-6-甲基-3-吡啶基]乙酰胺,其酸加成盐或其溶剂合物。

    MEASUREMENT METHOD FOR PHYSIOLOGICALLY ACTIVE SUBSTANCE OF BIOLOGICAL ORIGIN, AND REAGENT KIT FOR MEASUREMENT
    60.
    发明申请
    MEASUREMENT METHOD FOR PHYSIOLOGICALLY ACTIVE SUBSTANCE OF BIOLOGICAL ORIGIN, AND REAGENT KIT FOR MEASUREMENT 审中-公开
    生物原始生理活性物质的测量方法和测量试剂盒的测量方法

    公开(公告)号:US20130052657A1

    公开(公告)日:2013-02-28

    申请号:US13580638

    申请日:2010-02-26

    Inventor: Katsumi Yabusaki

    CPC classification number: G01N33/579 G01N33/551

    Abstract: Disclosed is a technique which simplifies the adjustment of a reagent which makes the proteins contained in limulus amoebocyte lysate (LAL) attach to the surface of microparticles dispersed in a prepared drug solution, and which can improve the accuracy of the detection of a predetermined physiologically active substance or the measurement of the concentration thereof. A reagent is prepared which adsorbs the proteins contained in LAL to beads dispersed in a drug solution prepared in advance. By reacting a sample containing an endotoxin with the reagent, groups of the beads associate and rapidly form large aggregates, and measurement of the endotoxin is carried out by the detecting the formation of the aggregates. The beads are formed from an inorganic material such as alumina, kaolin, or manganese oxide.

    Abstract translation: 公开了一种简化使鲎变形细胞裂解物(LAL)中含有的蛋白质附着于分散在制备药液中的微粒表面的试剂调整的技术,能够提高预定的生理活性物质的检测精度 物质或其浓度的测量。 制备将LAL中包含的蛋白质吸附到预先制备的药物溶液中的珠粒的试剂。 通过使含有内毒素的样品与试剂反应,珠的组合并快速形成大的聚集体,并且通过检测聚集体的形成来进行内毒素的测量。 珠粒由无机材料如氧化铝,高岭土或氧化锰形成。

Patent Agency Ranking